相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
40.0%
招募中
3
60.0%
暂无批准数据
- Innovative Molecules GmbH has dosed the first patient in its Phase 2a proof-of-concept trial evaluating adibelivir (IM-250) for recurrent genital herpes. - Adibelivir is a novel oral helicase-primase inhibitor with a mechanism distinct from nucleoside analogues, potentially addressing acyclovir-resistant HSV strains. - The study will assess safety, antiviral activity, pharmacokinetics, and clinical efficacy, with HSV shedding reduction as a key endpoint predictive of downstream suppression benefit. - The company is also advancing an EBV antiviral program through IND-enabling activities, leveraging the conserved helicase-primase complex across herpesviruses.
- Innovative Molecules GmbH has completed enrollment in the Phase 1b portion of its clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor for recurrent genital herpes. - The placebo-controlled study assesses safety, efficacy, and pharmacokinetics of once-weekly oral dosing in patients with recurrent genital herpes. - IM-250 represents potential innovation in a market that has seen little therapeutic advancement in over four decades. - Topline results from the Phase 1b portion are expected in the second half of 2025.
